Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Wilkinson

Showing results (161-170 of 190) with videos related to

Pageof 19
Sort By:
The Journal of Clinical Investigation|February 7, 1998
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitorsR B Kim, M F Fromm, C Wandel, et al.
Pharmacogenetics|August 1, 1996
Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-AmericansT I Edeki, J A Goldstein, S M de Morais, et al.
Clinical Pharmacology and Therapeutics|November 1, 1986
Reduction of liver plasma flow by caffeine and theophyllineJ Onrot, O Shaheen, I Biaggioni, et al.
Clinical Pharmacology and Therapeutics|December 9, 1997
Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitisP A Arns, A Adedoyin, A M DiBisceglie, et al.
Clinical Pharmacology and Therapeutics|May 24, 2001
CYP3A activity in European American and Japanese men using midazolam as an in vivo probeT Tateishi, M Watanabe, H Nakura, et al.
Clinical Pharmacology and Therapeutics|May 1, 1996
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolismK E Thummel, D O'Shea, M F Paine, et al.
Circulation|April 1, 1987
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequencesL A Siddoway, K A Thompson, C B McAllister, et al.
Clinical Pharmacology and Therapeutics|October 8, 1999
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503AM T Kinirons, D O'Shea, R B Kim, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1996
In vivo and in vitro characterization of CYP2E1 activity in Japanese and CaucasiansR B Kim, H Yamazaki, K Chiba, et al.
The American Journal of Cardiology|September 1, 1980
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamideD M Roden, S B Reele, S B Higgins, et al.
Pageof 19

Showing results (161-170 of 190) with videos related to

Sort By:
Pageof 19
The Journal of Clinical Investigation|February 7, 1998
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitorsR B Kim, M F Fromm, C Wandel, et al.
Pharmacogenetics|August 1, 1996
Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-AmericansT I Edeki, J A Goldstein, S M de Morais, et al.
Clinical Pharmacology and Therapeutics|November 1, 1986
Reduction of liver plasma flow by caffeine and theophyllineJ Onrot, O Shaheen, I Biaggioni, et al.
Clinical Pharmacology and Therapeutics|December 9, 1997
Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitisP A Arns, A Adedoyin, A M DiBisceglie, et al.
Clinical Pharmacology and Therapeutics|May 24, 2001
CYP3A activity in European American and Japanese men using midazolam as an in vivo probeT Tateishi, M Watanabe, H Nakura, et al.
Clinical Pharmacology and Therapeutics|May 1, 1996
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolismK E Thummel, D O'Shea, M F Paine, et al.
Circulation|April 1, 1987
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequencesL A Siddoway, K A Thompson, C B McAllister, et al.
Clinical Pharmacology and Therapeutics|October 8, 1999
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503AM T Kinirons, D O'Shea, R B Kim, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1996
In vivo and in vitro characterization of CYP2E1 activity in Japanese and CaucasiansR B Kim, H Yamazaki, K Chiba, et al.
The American Journal of Cardiology|September 1, 1980
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamideD M Roden, S B Reele, S B Higgins, et al.
Pageof 19